Projects, DesignResources, Software
For example, alternative excipient choices to develop improved, refrigerated stable mRNA vaccine formulations, e.g., as either liquid or lyophilized products, could be pursued. From the above discussion, one can see that stability assessments of mRNA vaccine candidates are in their infancy with only...
–dominant immune-mediated hepatitis.178As the largest secondary lymphoid organ and host of a wide range of immunologic functions, the spleen is an irreplaceable terminus of vaccines. A novel LNP named YK009-LNP shows a favorable biodistribution pattern in the spleen and the primarily skeletal muscl...
Pharmacological compositions for oral use can be made using a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries if desired, to obtain tablets or dragee cores. Suitable excipients include, but are not limited to, ...
droplet sizes of MF59-like compositions were 151–199 nm compared to 144 nm for shark squalene MF59-like emulsion. Some terpenoid oils were not successfully formulated in the SE excipient composition: compounds 1 and ether 6 were too viscous to be formulated, and acids C and diols B res...
The bottom row shows the exterior morphology of the powder, which consists of smooth round particles as expected, with trehalose as the excipient (Osanlóo, Fransson, Bergenståhl, & Millqvist-Fureby, 2023). The top row shows the interior morphology of the particles. The foam-like interior ...
the vaccine formulation may further comprise excipients such as, but not limited to, povidone and lactose. Povidone (polyvinylpyrrolidone) is routinely used in the pharmaceutical industry as a synthetic polymer vehicle for dispersing and suspending drugs. Lactose is also a commonly used excipient in ...
1.An immunogenic composition comprising a vector encoding at least one epitope from at least three antigens encoded by a gene selected from the group consisting of MUC1, HER2, hTERT, Survivin, MAGEA3 and Mammaglobin A, and at least one pharmaceutically acceptable excipient. ...
“Excipient” refers to any component of a vaccine that is not an antigen. “Dose” refers to a vaccine or immunogenic composition given to a subject. A “first dose” or “priming vaccine” refers to the dose of such a composition given on Day 0. A “second dose” or a “third dose...